Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Genetic Testing Market Report 2026-2034 by Tests, Products, Technology, Disease, End-Users, Countries, and Companies | NGS and D2C Demand Propel Market to US$ 50.29 Billion

globenewswire.com
ABT Abbott Laboratories is mentioned as a key player in the genetic testing market, which is projected to grow significantly. The article does not provide specific sentiment for Abbott, but its inclusion as a major company suggests potential benefit from market growth. DHR Danaher Corporation, through its subsidiary Cepheid Inc., is identified as a key player in the expanding genetic testing market. The article does not offer specific sentiment but includes it among major companies in the sector. ILMN Illumina Inc. is listed as a key company in the genetic testing market, which is experiencing strong growth driven by advances in sequencing technology. The article does not provide specific sentiment for Illumina. BIO Bio-Rad Laboratories Inc. is mentioned as a key player in the genetic testing market. The article does not provide specific sentiment for the company, but its inclusion indicates its role in a growing industry. TMO Thermo Fisher Scientific Inc. is listed as a key company in the genetic testing market. The article does not provide specific sentiment for the company, but its role as a major player in a growing industry is highlighted. MYGN Myriad Genetics is highlighted for launching SneakPeek, an at-home gender test distributed through numerous U.S. retail stores, indicating successful expansion and consumer accessibility in the growing genetic testing market. PRPH ProPhase Labs is mentioned positively for launching DNA Complete, Inc., a subsidiary focused on accessible D2C DNA testing, indicating strategic expansion into a growing segment of the genetic testing market.

Global Genetic Testing Market Report 2026-2034 by Tests, Products, Technology, Disease, End-Users, Countries, and Companies | NGS and D2C Demand Propel Market to US$ 50.29 Billion Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Genetic Testing Market Report by Tests, Products, Technology, Disease, End-Users, Countries and Company Analysis 2026-2034" has been added to ResearchAndMarkets.com's offering.

The global genetic testing market is projected to grow from US$ 21.84 billion in 2025 to US$ 50.29 billion by 2034, registering a compound annual growth rate of 9.71% from 2026 to 2034. Market expansion is supported by rising demand for personalized medicine, advances in next-generation sequencing, broader access to direct-to-consumer testing, and increased awareness of preventive healthcare.

Genetic testing is gaining importance across predictive screening, oncology, pharmacogenomics, prenatal assessment, carrier testing, rare disease diagnosis, and wellness applications. Technologies including PCR, DNA sequencing, microarrays, DNA methylation analysis, and SNP-based profiling are improving accuracy, scalability, and clinical utility. Continued reductions in sequencing costs, combined with expanding laboratory capabilities and digital-health integration, are strengthening adoption among healthcare providers and consumers.

Key Genetic Testing Market Growth Drivers

Demand for comprehensive wellness and epigenetic testing is creating new commercial opportunities. In October 2024, EpiMedTech introduced epiGeneComplete, which evaluates aging markers, metabolic performance, inflammation, stress responses, and other biological indicators using next-generation sequencing, DNA methylation analysis, and SNP markers. Growing interest in longevity, fitness, and proactive health management is increasing demand for lifestyle-focused genomic services.

The direct-to-consumer segment is also expanding as at-home kits provide convenient access to ancestry, health predisposition, nutrition, and wellness insights. In November 2024, ProPhase Labs launched DNA Complete, Inc., a wholly owned subsidiary focused on accessible D2C DNA testing. Improved digital reporting, wider distribution, stronger privacy controls, and greater regulatory clarity are supporting consumer adoption.

Retail availability is further improving genetic testing accessibility. In November 2024, Myriad Genetics launched SneakPeek, an at-home gender test distributed through more than 8,800 U.S. retail stores. The growing presence of prenatal tests, ancestry kits, disease-risk screening products, and wellness assessments across pharmacies, supermarkets, and online marketplaces is bringing genetic testing into routine consumer healthcare.

Market Challenges

Data privacy and regulatory compliance remain significant concerns. Genetic information requires stringent safeguards against unauthorized access, third-party sharing, and discriminatory use. Compliance with GDPR, HIPAA, and country-specific genomic data regulations can increase operating costs, extend approval timelines, and complicate international expansion. Transparent data policies and secure infrastructure will be essential to maintaining consumer confidence.

High testing costs and unequal access also limit adoption, particularly in developing regions. Advanced equipment, specialized laboratory workflows, limited reimbursement, infrastructure gaps, and shortages of trained professionals restrict availability. Greater insurance coverage, lower operating costs, workforce development, and educational initiatives will be required to support broader global access.

Regional Genetic Testing Market Outlook

The United States remains a leading market due to its advanced healthcare infrastructure, substantial investment in precision medicine, and widespread acceptance of at-home testing. Genomic profiling is increasingly used in cancer diagnostics, carrier screening, and pharmacogenomics, while retail distribution and digital-health platforms are expanding consumer access.

Germany is experiencing steady growth in NGS-based diagnostics, oncology testing, rare disease detection, carrier screening, and pharmacogenomic evaluation. Strict regulatory standards support test reliability, while healthcare digitalization and expanding diagnostic laboratory capacity are accelerating clinical adoption.

China is positioned among the fastest-growing genetic testing markets, supported by government investment in precision medicine, rising healthcare expenditure, and an expanding domestic biotechnology industry. Prenatal testing, oncology genomics, carrier screening, and health-risk assessment represent major opportunities, although data-privacy requirements continue to influence commercial strategies.

Saudi Arabia is advancing genetic testing through healthcare modernization and precision medicine programs associated with Vision 2030. Demand is particularly strong for premarital, carrier, newborn, oncology, and rare disease screening. Government initiatives, private-sector investment, and partnerships with global diagnostic companies are strengthening local laboratory capabilities.

Recent Genetic Testing Industry Developments

Genetic Testing Market Segmentation

Geographic Coverage: The report examines the United States and Canada in North America; France, Germany, Italy, Spain, the United Kingdom, Belgium, the Netherlands, and Turkey in Europe; China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, and New Zealand in Asia Pacific; Brazil, Mexico, and Argentina in Latin America; and Saudi Arabia, the UAE, and South Africa in the Middle East & Africa.

Competitive Landscape

The genetic testing market report evaluates major companies through corporate overviews, key personnel, recent developments, SWOT analysis, and revenue analysis. Companies covered include Abbott Laboratories, Danaher Corporation through Cepheid Inc., Illumina Inc., Bio-Rad Laboratories Inc., F Hoffmann-La Roche AG, DiaSorin, Revvity Inc., and Thermo Fisher Scientific Inc.

Ongoing innovation in sequencing, predictive analytics, consumer testing, and clinical genomics is expected to reshape the competitive landscape through 2034. Companies that combine validated testing platforms, secure data management, broad distribution, and actionable clinical insights will be well positioned to capture opportunities across diagnostic, predictive, and personalized healthcare applications.

Key Attributes

Key Topics Covered

1. Introduction

2. Research & Methodology

2.1 Data Source

2.1.1 Primary Sources

2.1.2 Secondary Sources

2.2 Research Approach

2.2.1 Top-Down Approach

2.2.2 Bottom-Up Approach

2.3 Forecast Projection Methodology

3. Executive Summary

4. Market Dynamics

4.1 Growth Drivers

4.2 Challenges

5. Global Genetic Testing Market

5.1 Historical Market

5.2 Market Forecast

6. Market Share Analysis

6.1 By Type

6.2 By Product

6.3 By Technology

6.4 By Disease

6.5 By End User

6.6 By Countries

7. Type

Historical Market and Market Forecast

7.1 Predictive Testing

7.2 Carrier Testing

7.3 Prenatal and Newborn Testing

7.4 Diagnostic Testing

7.5 Pharmacogenomic Testing

7.6 Nutrigenomic Testing

7.7 Others

8. Product

Historical Market and Market Forecast

8.1 Consumables

8.2 Equipments

8.3 Software & Services

9. Technology

Historical Market and Market Forecast

9.1 PCR

9.2 DNA Sequencing

9.3 Microarrays

9.4 Others

10. Disease

Historical Market and Market Forecast

10.1 Cancer

10.2 Genetic Diseases

10.3 Cardiovascular Diseases

10.4 Rare Diseases

10.5 Infectious Diseases

10.6 Others

11. End User

Historical Market and Market Forecast

11.1 Hospitals & Clinics

11.2 Diagnostic Laboratories

11.3 Others

12. Countries

Historical Market and Market Forecast

12.1 North America

12.1.1 United States

12.1.2 Canada

12.2 Europe

12.2.1 France

12.2.2 Germany

12.2.3 Italy

12.2.4 Spain

12.2.5 United Kingdom

12.2.6 Belgium

12.2.7 Netherlands

12.2.8 Turkey

12.3 Asia Pacific

12.3.1 China

12.3.2 Japan

12.3.3 India

12.3.4 Australia

12.3.5 South Korea

12.3.6 Thailand

12.3.7 Malaysia

12.3.8 Indonesia

12.3.9 New Zealand

12.4 Latin America

12.4.1 Brazil

12.4.2 Mexico

12.4.3 Argentina

12.5 Middle East & Africa

12.5.1 South Africa

12.5.2 Saudi Arabia

12.5.3 UAE

13. Porter's Five Forces Analysis

13.1 Bargaining Power of Buyers

13.2 Bargaining Power of Suppliers

13.3 Degree of Competition

13.4 Threat of New Entrants

13.5 Threat of Substitutes

14. SWOT Analysis

14.1 Strength

14.2 Weakness

14.3 Opportunity

14.4 Threats

15. Key Players Analysis

Company analysis covers Overviews, Key Person, Recent Developments, SWOT Analysis and Revenue Analysis.

15.1 Abbott Laboratories

15.2 Danaher Corporation (Cepheid Inc.)

15.3 Illumina Inc.

15.4 BioRad Laboratories Inc.

15.5 F Hoffmann-La Roche AG

15.6 Diasorin

15.7 Revvity Inc.

15.8 Thermo Fisher Scientific Inc.

For more information about this report visit https://www.researchandmarkets.com/r/2yp5gl

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.